Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms Lighthouse
- 13 Jul 2017 Planned End Date changed from 1 Jun 2020 to 1 Jun 2018.
- 13 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2017.
- 13 Jul 2017 Status changed from recruiting to active, no longer recruiting.